Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Department of Anesthesiology, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Am J Med Genet A. 2021 Oct;185(10):3012-3018. doi: 10.1002/ajmg.a.62402. Epub 2021 Jun 21.
Identifying hereditary syndromes among patients with renal cell carcinoma (RCC) is essential for surveillance of affected individuals and their at-risk family members and for treatment optimization. We conducted a chart review to determine the percentage of patients with RCC who were seen at the University of Miami Health System (UHealth), and met the American College of Medical Genetics (ACMG) and the National Society of Genetic Counselors (NSGC) genetic referral criteria at the University of Miami. Subsequently, we determined the percentage of those who went on to receive genetic evaluation. Patients selected by International Classification of Diseases (ICD) 9/10 codes corresponding to kidney cancer who were at least 18 years of age at the time of diagnosis were included in the study. We included a total of 1443 patients in the final analysis, and after exclusion of charts with incorrect ICD codes, insufficient clinical data, unknown pathology, and patients who were not seen. We used chi-square analysis, ANOVA, and t-test. Of 1443 charts reviewed, 65.7% were male and 34.3% were female. 47.7% self-identified as White, 39.2% as Hispanic, 9.1% as Black, and 4.0% as "other." The mean age of RCC diagnosis was 60.0 ± 12.4 years old. In total, 47.0% of patients met ACMG/NSGC referral criteria for genetic evaluation. Of those, only 4.2% had documented genetic assessment. This study showed a low adherence to ACMG/NSGC genetic referral guidelines at our institution and a need for increasing patients' and practitioners' awareness about the significance of genetic assessment for RCC patients and their family members.
确定患有肾细胞癌 (RCC) 的患者中是否存在遗传性综合征对于受影响个体及其高危家庭成员的监测以及治疗优化至关重要。我们进行了病历回顾,以确定在迈阿密大学健康系统 (UHealth) 就诊的 RCC 患者的百分比,这些患者符合美国医学遗传学学院 (ACMG) 和国家遗传咨询师协会 (NSGC) 的遗传转诊标准,并在迈阿密大学接受了遗传评估。随后,我们确定了接受遗传评估的患者比例。本研究纳入了至少在诊断时年满 18 岁且使用国际疾病分类 (ICD) 9/10 码对应肾脏癌症的患者。最终分析共纳入 1443 例患者,排除 ICD 编码错误、临床资料不足、病理不明以及未就诊的患者后。我们使用卡方检验、方差分析和 t 检验。在回顾的 1443 份病历中,65.7%为男性,34.3%为女性。47.7%的患者自我认定为白人,39.2%为西班牙裔,9.1%为黑人,4.0%为“其他”。RCC 诊断的平均年龄为 60.0±12.4 岁。总的来说,47.0%的患者符合 ACMG/NSGC 遗传评估转诊标准。但仅有 4.2%的患者进行了遗传评估。本研究表明,我们机构对 ACMG/NSGC 遗传转诊指南的遵循率较低,需要提高患者和医生对遗传评估对 RCC 患者及其家庭成员的重要性的认识。